Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

An Unusually Large Carbuncle of the Temporofacial Region

Published: Mon, 26 Jun 2017 12:00:00 EDT
How was this extensive carbuncle over the temporofacial region effectively managed?
Wounds

Management of the Diabetic Patient Needing Emergency Surgery

Published: Mon, 26 Jun 2017 12:00:00 EDT
The emergency surgical patient with diabetes presents unique challenges, and is often considered high risk. What can be done to improve outcomes for these patients?
BJA Education

Severe Polyserositis Induced by PCV13 Vaccine

Published: Mon, 26 Jun 2017 12:00:00 EDT
Was the severe serositis in this 75-year-old woman an auto-inflammatory response to her recent vaccination with 13-valent pneumococcal conjugate vaccine?
Journal of Medical Case Reports

Delayed Second Dose Antibiotics for Patients With Sepsis

Published: Mon, 26 Jun 2017 12:00:00 EDT
How might delays in second antibiotic administration affect outcomes among patients admitted with sepsis?
Critical Care Medicine
Displaying results 17-20 (of 20)
 1 - 2 - 3 - 4 - 5 

HEALTHCARE SUPPLIER NEWS

R&D costs growing, Roche shines and Novo high for ROI: It’s the EP report

Published: Tue, 20 Jun 2017 12:32:42 +0000
EvaluatePharma says spending on global pharma research will hit $181 billion in five years as Roche, AbbVie and AstraZeneca are seen as having some of the biggest potential pipeline meds.

Ionis’ Akcea closes in on $125M IPO to fund phase 3 trials

Published: Tue, 20 Jun 2017 12:10:55 +0000
Akcea Therapeutics is closing in on an IPO expected to gross in the region of $125 million. The Ionis Pharmaceuticals’ lipid disorder subsidiary plans to spend most of the money on the generation of phase 3 data to support the approval of volanesorsen in two indications.

Novartis' longer-acting AMD drug matches archrival Eylea in phase 3 trials

Published: Tue, 20 Jun 2017 11:46:43 +0000
Filings for brolucizumab are expected next year, with analysts at Jefferies predicting $2 billion in peak sales for the drug.

Parexel to go private in $5B Pamplona Capital buyout deal

Published: Tue, 20 Jun 2017 11:24:11 +0000
After growing rumors this week, Parexel has become the latest CRO to be bought up as the industry continues its M&A bonanza.
Displaying results 21-24 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top